^
Association details:
| Biomarker: | KIF5B-RET fusion + TP53 H193R + MYC amplification |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Gavreto (pralsetinib) (RET inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
EP08.02-037 - Small Cell Transformation in a Patient with RET Fusion Positive Lung Adenocarcinoma on Pralsetinib.
Published date:
07/12/2022
Excerpt:
A 72-year-old never smoker male patient was diagnosed with lung adenocarcinoma...Molecular workup (MCSTP) identified a KIF5B::RET fusion along with a loss-of-function mutation in TP53 (H193R) and MYC amplification….Pralsetinib was resumed following completion of radiation therapy, however further progression was detected 2 months later in the chest, abdomen and brain with fistula formation between the right mainstem bronchus and the subcarinal lymph node block.
